-
1
-
-
0024394527
-
Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three fold rise in Crohn's disease
-
Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three fold rise in Crohn's disease. Gut 1989; 30: 618-22
-
(1989)
Gut
, vol.30
, pp. 618-622
-
-
Barton, J.R.1
Gillon, S.2
Ferguson, A.3
-
2
-
-
0031019969
-
Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity and mortality in a regional cohort
-
Langholz E, Munkholm P, Kraslinikoff PA, et al. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity and mortality in a regional cohort. Scand J Gastroenterol 1997; 32: 139-47
-
(1997)
Scand J Gastroenterol
, vol.32
, pp. 139-147
-
-
Langholz, E.1
Munkholm, P.2
Kraslinikoff, P.A.3
-
3
-
-
0242330303
-
Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: A state-wide population based study
-
Kugathasan S, Judd RH, Hoffman RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a state-wide population based study. J Pediatr 2003; 143: 525-31
-
(2003)
J Pediatr
, vol.143
, pp. 525-531
-
-
Kugathasan, S.1
Judd, R.H.2
Hoffman, R.G.3
-
4
-
-
0033959385
-
Inflammatory bowel disease in Iceland, 1990-1994: A prospective, nationwide, epidemiological study
-
Bjornsson S, Johansson JH. Inflammatory bowel disease in Iceland, 1990-1994: a prospective, nationwide, epidemiological study. Eur J Gatroenterol Hepatol 2000; 12: 31-8
-
(2000)
Eur J Gatroenterol Hepatol
, vol.12
, pp. 31-38
-
-
Bjornsson, S.1
Johansson, J.H.2
-
5
-
-
0032981503
-
Inflammatory bowel disease in pediatric and adolescent patients
-
Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am 1999; 28: 445-58
-
(1999)
Gastroenterol Clin North Am
, vol.28
, pp. 445-458
-
-
Baldassano, R.N.1
Piccoli, D.A.2
-
6
-
-
0141682647
-
Inflammatory bowel disease in early childhood and adolescents: Special considerations
-
Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescents: special considerations. Gastroenterol Clin North Am 2003; 32: 967-95
-
(2003)
Gastroenterol Clin North Am
, vol.32
, pp. 967-995
-
-
Mamula, P.1
Markowitz, J.E.2
Baldassano, R.N.3
-
7
-
-
0033227692
-
-
Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 1999; 5: 285-94
-
Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 1999; 5: 285-94
-
-
-
-
8
-
-
10044265135
-
Why do anti-tumor necrosis factor antibodies work in Crohn's disease?
-
Sands BE. Why do anti-tumor necrosis factor antibodies work in Crohn's disease? Rev Gastroenterol Disord 2004; 4 Suppl. 3: S10-7
-
(2004)
Rev Gastroenterol Disord
, vol.4
, Issue.SUPPL. 3
-
-
Sands, B.E.1
-
9
-
-
0033778364
-
Tumor necrosis factor: Biology and therapeutic inhibitors
-
Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148-57
-
(2000)
Gastroenterology
, vol.119
, pp. 1148-1157
-
-
Papadakis, K.A.1
Targan, S.R.2
-
10
-
-
0031849974
-
Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites
-
Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998; 188: 373-86
-
(1998)
J Exp Med
, vol.188
, pp. 373-386
-
-
Dieu, M.C.1
Vanbervliet, B.2
Vicari, A.3
-
11
-
-
0026717674
-
The pathophysiology of tumor necrosis factors
-
Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-52
-
(1992)
Annu Rev Immunol
, vol.10
, pp. 411-452
-
-
Vassalli, P.1
-
12
-
-
0032522666
-
A p55 TNF receptor immunoadhesion prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production
-
Pender SL, Fell JM, Chamow SM, et al. A p55 TNF receptor immunoadhesion prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998; 160: 4098-103
-
(1998)
J Immunol
, vol.160
, pp. 4098-4103
-
-
Pender, S.L.1
Fell, J.M.2
Chamow, S.M.3
-
14
-
-
0031596842
-
Methotrexate in patients with Crohn's disease after 6-mercaptopurine
-
Mack DR, Young R, Kaufmann SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998; 132: 830-5
-
(1998)
J Pediatr
, vol.132
, pp. 830-835
-
-
Mack, D.R.1
Young, R.2
Kaufmann, S.S.3
-
15
-
-
0025009896
-
Azathioprine in the treatment of children with inflammatory bowel disease
-
Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990; 117: 809-14
-
(1990)
J Pediatr
, vol.117
, pp. 809-814
-
-
Verhave, M.1
Winter, H.S.2
Grand, R.J.3
-
16
-
-
0031680256
-
Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease
-
Kirschner B. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813-21
-
(1998)
Gastroenterology
, vol.115
, pp. 813-821
-
-
Kirschner, B.1
-
17
-
-
0033761188
-
Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
-
Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000; 95: 3189-94
-
(2000)
Am J Gastroenterol
, vol.95
, pp. 3189-3194
-
-
Kugathasan, S.1
Werlin, S.L.2
Martinez, A.3
-
18
-
-
37549065631
-
A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): 'top down' vs. 'step up' strategies
-
abstract no. W1017, May 14-19; Chicago IL
-
Hommes D, Baert F, van Assche G, et al. A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): 'top down' vs. 'step up' strategies [abstract no. W1017]. Digestive Diseases Week conference; 2005 May 14-19; Chicago (IL)
-
(2005)
Digestive Diseases Week conference
-
-
Hommes, D.1
Baert, F.2
van Assche, G.3
-
19
-
-
13944252969
-
Hepatosplenic T cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn's disease
-
Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn's disease. J Pediatr Gastroenterol Nutr 2005; 40: 220-2
-
(2005)
J Pediatr Gastroenterol Nutr
, vol.40
, pp. 220-222
-
-
Thayu, M.1
Markowitz, J.E.2
Mamula, P.3
-
20
-
-
0029004771
-
Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
-
Scallon BJ, Moore MA, Trinh H. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995; 7: 251-9
-
(1995)
Cytokine
, vol.7
, pp. 251-259
-
-
Scallon, B.J.1
Moore, M.A.2
Trinh, H.3
-
21
-
-
0038047689
-
Infliximab but not etanercept induces apoptosis in lamina propria T lymphocytes from patients with Crohn's disease
-
Van den Brande JM, Braat H, VanDen Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-85
-
(2003)
Gastroenterology
, vol.124
, pp. 1774-1785
-
-
Van den Brande, J.M.1
Braat, H.2
VanDen Brink, G.R.3
-
22
-
-
17744373658
-
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease
-
Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 14: 463-73
-
(2001)
Aliment Pharmacol Ther
, vol.14
, pp. 463-473
-
-
Cornillie, F.1
Shealy, D.2
D'Haens, G.3
-
23
-
-
0038184193
-
Infliximab (Remicade) therapy in the treatment of pediatric Crohn's disease
-
Baldassano R, Braeger CP, Escher JC, et al. Infliximab (Remicade) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003; 98: 833-8
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 833-838
-
-
Baldassano, R.1
Braeger, C.P.2
Escher, J.C.3
-
24
-
-
0033842357
-
Use of infliximab in the treatment of Crohn's disease in children and adolescents
-
Hyams JS, Markowitz J, Wylie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000; 137: 192-6
-
(2000)
J Pediatr
, vol.137
, pp. 192-196
-
-
Hyams, J.S.1
Markowitz, J.2
Wylie, R.3
-
25
-
-
0037259135
-
Safety and steroid sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center
-
Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 104-11
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 104-111
-
-
Stephens, M.C.1
Shepanski, M.A.2
Mamula, P.3
-
26
-
-
9144234882
-
Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease
-
Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004; 10: 745-50
-
(2004)
Inflamm Bowel Dis
, vol.10
, pp. 745-750
-
-
Lamireau, T.1
Cezard, J.P.2
Dabadie, A.3
-
27
-
-
33748147712
-
Corticosteroid therapy in the age of infliximab: Acute and 1 year outcomes in newly diagnosed children with Crohn's disease
-
Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1 year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1124-9
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 1124-1129
-
-
Markowitz, J.1
Hyams, J.2
Mack, D.3
-
28
-
-
0141613187
-
A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factor (Remicade®) in severe pediatric Crohn's disease
-
Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factor (Remicade®) in severe pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2003; 36: 632-6
-
(2003)
J Pediatr Gastroenterol Nutr
, vol.36
, pp. 632-636
-
-
Cezard, J.P.1
Nouaili, N.2
Talbotec, C.3
-
29
-
-
14644440656
-
Infliximab therapy in 30 patients with refractory pediatric Crohn's disease with and without fistulas in The Netherlands
-
de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn's disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004; 39: 46-52
-
(2004)
J Pediatr Gastroenterol Nutr
, vol.39
, pp. 46-52
-
-
de Ridder, L.1
Escher, J.C.2
Bouquet, J.3
-
30
-
-
0042329252
-
Response to infliximab is related to disease duration in paediatric Crohn's disease
-
Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003; 18: 425-31
-
(2003)
Aliment Pharmacol Ther
, vol.18
, pp. 425-431
-
-
Lionetti, P.1
Bronzini, F.2
Salvestrini, C.3
-
31
-
-
0034108994
-
Azathioprine and 6-meracptopurine for the treatment of perianal Crohn's disease in children
-
Jeshion WC, Larsen KL, Jawad AF, et al. Azathioprine and 6-meracptopurine for the treatment of perianal Crohn's disease in children. J Clin Gastroenterol 2000; 30: 294-8
-
(2000)
J Clin Gastroenterol
, vol.30
, pp. 294-298
-
-
Jeshion, W.C.1
Larsen, K.L.2
Jawad, A.F.3
-
32
-
-
0024244814
-
Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease
-
Kanof M, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95: 1523-7
-
(1988)
Gastroenterology
, vol.95
, pp. 1523-1527
-
-
Kanof, M.1
Lake, A.M.2
Bayless, T.M.3
-
33
-
-
4544305960
-
Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease
-
Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004; 36: 342-7
-
(2004)
Dig Liver Dis
, vol.36
, pp. 342-347
-
-
Borrelli, O.1
Bascietto, C.2
Viola, F.3
-
34
-
-
30344431805
-
Infliximab dependency in a national cohort of children with Crohn's disease
-
Wewer V, Riis L, Vind I, et al. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr 2006; 42: 40-5
-
(2006)
J Pediatr Gastroenterol Nutr
, vol.42
, pp. 40-45
-
-
Wewer, V.1
Riis, L.2
Vind, I.3
-
35
-
-
37549042126
-
Pathogenesis of immunological/inflammatory GI disease and IBD [abstract no. 86]
-
Benkov KJ, Vorha P, Pittman NS, et al. Pathogenesis of immunological/inflammatory GI disease and IBD [abstract no. 86]. J Pediatr Gastroenterol Nutr 1996; 23: 363
-
(1996)
J Pediatr Gastroenterol Nutr
, vol.23
, pp. 363
-
-
Benkov, K.J.1
Vorha, P.2
Pittman, N.S.3
-
36
-
-
0033770169
-
A multicenter trial of 6-mercaptopurine and prednisone with newly diagnosed Crohn's disease
-
Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902
-
(2000)
Gastroenterology
, vol.119
, pp. 895-902
-
-
Markowitz, J.1
Grancher, K.2
Kohn, N.3
-
38
-
-
33947397636
-
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
-
Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73
-
(2007)
Gastroenterology
, vol.132
, pp. 863-873
-
-
Hyams, J.1
Crandall, W.2
Kugathasan, S.3
-
39
-
-
0037247042
-
Infusion reactions to infliximab in children and adolescents: Frequency, outcome and a predictive model
-
Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17: 75-84
-
(2003)
Aliment Pharmacol Ther
, vol.17
, pp. 75-84
-
-
Crandall, W.V.1
Mackner, L.M.2
-
41
-
-
0038649858
-
The incidence and management of infusion reactions to infliximab: A large center experience
-
Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 1315-1324
-
-
Cheifetz, A.1
Smedley, M.2
Martin, S.3
-
42
-
-
10744224387
-
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
-
Rutgeerts P, Feagan BG, Lichtenstein G, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13
-
(2004)
Gastroenterology
, vol.126
, pp. 402-413
-
-
Rutgeerts, P.1
Feagan, B.G.2
Lichtenstein, G.3
-
43
-
-
14044252848
-
Adalimumab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept
-
Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 251-8
-
(2005)
Aliment Pharmacol Ther
, vol.21
, pp. 251-258
-
-
Shen, C.1
Assche, G.V.2
Colpaert, S.3
-
44
-
-
33645651405
-
Drug insight: Antagonists of tumor necrosis factor-α in the treatment of inflammatory bowel disease
-
Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor necrosis factor-α in the treatment of inflammatory bowel disease. Nat Clin Pract 2006; 3: 220-8
-
(2006)
Nat Clin Pract
, vol.3
, pp. 220-228
-
-
Chang, J.T.1
Lichtenstein, G.R.2
-
45
-
-
32044451548
-
Human anti tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I Trial
-
Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I Trial. Gastroenterology 2006; 130: 323-33
-
(2006)
Gastroenterology
, vol.130
, pp. 323-333
-
-
Hanauer, S.B.1
Sandborn, W.J.2
Rutgeerts, P.3
-
46
-
-
29444442072
-
Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: Results of a blinded, placebo-controlled study [abstract no. 843]
-
S
-
Sandborn WJ, Hanauer SB, Lukas M, et al. Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of a blinded, placebo-controlled study [abstract no. 843]. Am J Gastroenterol 2005; 100 Suppl. S: S311
-
(2005)
Am J Gastroenterol
, vol.100
, Issue.SUPPL.
-
-
Sandborn, W.J.1
Hanauer, S.B.2
Lukas, M.3
-
47
-
-
33846242958
-
Adalimumab for maintenance of clinical response in patients with Crohn's disease: The CHARM Trial
-
Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response in patients with Crohn's disease: the CHARM Trial. Gastroenterol 2007; 132: 52-65
-
(2007)
Gastroenterol
, vol.132
, pp. 52-65
-
-
Colombel, J.F.1
Sandborn, W.J.2
Rutgeerts, P.3
-
48
-
-
7044226437
-
An open label study of the human anti-tnf monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease
-
Sandborn WJ, Hanauer S, Loftus EV, et al. An open label study of the human anti-tnf monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99: 1984-9
-
(2004)
Am J Gastroenterol
, vol.99
, pp. 1984-1989
-
-
Sandborn, W.J.1
Hanauer, S.2
Loftus, E.V.3
-
49
-
-
37549047302
-
-
Hinojosa J, Gomollon F, Nos P, et al. Four week results of adalimumab treatment in subjects with fistulizing Crohn's disease who have failed response or showed intolerance to infliximab [abstract no. 815]. Digestive Diseases Week; 2006 May 19-24; Los Angeles (CA)
-
Hinojosa J, Gomollon F, Nos P, et al. Four week results of adalimumab treatment in subjects with fistulizing Crohn's disease who have failed response or showed intolerance to infliximab [abstract no. 815]. Digestive Diseases Week; 2006 May 19-24; Los Angeles (CA)
-
-
-
-
50
-
-
24644445063
-
Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease
-
Mian S, Baron H. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr 2005; 41 (3): 357-9
-
(2005)
J Pediatr Gastroenterol Nutr
, vol.41
, Issue.3
, pp. 357-359
-
-
Mian, S.1
Baron, H.2
-
51
-
-
0034800239
-
Surpassing conventional therapies: The role of biologic therapy
-
Baldassano RN. Surpassing conventional therapies: the role of biologic therapy. J Pediatr Gastroenterol Nutr 2001; 33: S19-26
-
(2001)
J Pediatr Gastroenterol Nutr
, vol.33
-
-
Baldassano, R.N.1
-
52
-
-
4344702394
-
Recent advances in biological therapy for inflammatory bowel disease
-
Kurtovic J, Segal I. Recent advances in biological therapy for inflammatory bowel disease. Trop Gastroenterol 2004; 25: 9-14
-
(2004)
Trop Gastroenterol
, vol.25
, pp. 9-14
-
-
Kurtovic, J.1
Segal, I.2
-
53
-
-
4644325814
-
CDP571, a humanized monoclonal antibody to tumor necrosis factor ?, for moderate to severe Crohn's disease: A randomized, double blind, placebo controlled trial
-
Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanized monoclonal antibody to tumor necrosis factor ?, for moderate to severe Crohn's disease: a randomized, double blind, placebo controlled trial. Gut 2004; 53: 1485-93
-
(2004)
Gut
, vol.53
, pp. 1485-1493
-
-
Sandborn, W.J.1
Feagan, B.G.2
Radford-Smith, G.3
-
54
-
-
9144261186
-
CDP-571, a humanized anti tumor necrosis factor ? monoclonal antibody in pediatric Crohn's disease
-
Mamula P, Cohen SA, Ferry GA, et al. CDP-571, a humanized anti tumor necrosis factor ? monoclonal antibody in pediatric Crohn's disease. Inflamm Bowel Dis 2004; 10: 723-30
-
(2004)
Inflamm Bowel Dis
, vol.10
, pp. 723-730
-
-
Mamula, P.1
Cohen, S.A.2
Ferry, G.A.3
-
55
-
-
0026080801
-
Thalidomide selectively inhibits tumor necrosis factor ? production by stimulated human monocytes
-
Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor ? production by stimulated human monocytes. J Exp Med 1991; 173: 699-703
-
(1991)
J Exp Med
, vol.173
, pp. 699-703
-
-
Sampaio, E.P.1
Sarno, E.N.2
Galilly, R.3
-
56
-
-
0035071241
-
Efficacy of long-term treatment with thalidomide in children and young adults with Crohn's disease: Preliminary results
-
Facchini S, Candusso M, Martelossi S, et al. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn's disease: preliminary results. J Pediatr Gastroenterol Nutr 2001; 32: 178-81
-
(2001)
J Pediatr Gastroenterol Nutr
, vol.32
, pp. 178-181
-
-
Facchini, S.1
Candusso, M.2
Martelossi, S.3
-
57
-
-
33749424855
-
Treatment with thalidomide in children and adolescents with inflammatory bowel disease
-
Martelossi S, Marchetti F, Lenhardt A, et al. Treatment with thalidomide in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39: S282
-
(2004)
J Pediatr Gastroenterol Nutr
, vol.39
-
-
Martelossi, S.1
Marchetti, F.2
Lenhardt, A.3
-
58
-
-
24144483087
-
A randomized placebo-controlled trial of certolizumab pegol (CDP 870) for treatment of Crohn's disease
-
Schreiber S, Rutgeerts P, Fedorak R, et al. A randomized placebo-controlled trial of certolizumab pegol (CDP 870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18
-
(2005)
Gastroenterology
, vol.129
, pp. 807-818
-
-
Schreiber, S.1
Rutgeerts, P.2
Fedorak, R.3
-
59
-
-
33144489771
-
Certolizumab pegol, a humanized anti-TNF pegylated FAb' fragment, is safe, and effective in the maintenance of response and remission following induction in active Crohn's disease: A phase III study (PRECiSE)
-
Schreiber S, Khaliq-Kareemi M, Lawrence I, et al. Certolizumab pegol, a humanized anti-TNF pegylated FAb' fragment, is safe, and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (PRECiSE). Gut 2005; 54 Suppl. VII: A82
-
(2005)
Gut
, vol.54
, Issue.SUPPL. VII
-
-
Schreiber, S.1
Khaliq-Kareemi, M.2
Lawrence, I.3
-
60
-
-
0037315157
-
Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumor necrosis factor receptor): Results of a randomized, open label, pilot study
-
Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumor necrosis factor receptor): results of a randomized, open label, pilot study. Aliment Pharmacol Ther 2003; 17: 185-92
-
(2003)
Aliment Pharmacol Ther
, vol.17
, pp. 185-192
-
-
Rutgeerts, P.1
Lemmens, L.2
Van Assche, G.3
-
61
-
-
33745608448
-
Onercept for moderate to severe Crohn's disease: A randomized, double blind, placebo controlled trial
-
Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate to severe Crohn's disease: a randomized, double blind, placebo controlled trial. Clin Gastroenterol Hepatol 2006; 4: 888-93
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 888-893
-
-
Rutgeerts, P.1
Sandborn, W.J.2
Fedorak, R.N.3
-
62
-
-
0034827790
-
Etanercept in the treatment of active refractory Crohn's disease: A single center pilot trial
-
D'Haens G, Swijsen C, Norman M, et al. Etanercept in the treatment of active refractory Crohn's disease: a single center pilot trial. Am J Gastroenterol 2001; 96: 2564-8
-
(2001)
Am J Gastroenterol
, vol.96
, pp. 2564-2568
-
-
D'Haens, G.1
Swijsen, C.2
Norman, M.3
-
63
-
-
0034754477
-
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
-
Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-94
-
(2001)
Gastroenterology
, vol.121
, pp. 1088-1094
-
-
Sandborn, W.J.1
Hanauer, S.B.2
Katz, S.3
-
64
-
-
0036142395
-
Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease
-
Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002; 122: 7-14
-
(2002)
Gastroenterology
, vol.122
, pp. 7-14
-
-
Hommes, D.1
van den Blink, B.2
Plasse, T.3
-
65
-
-
33646147141
-
Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry
-
Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry. Clin Gastroenterol Hepatol 2006; 4: 621-30
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 621-630
-
-
Lichtenstein, G.R.1
Feagan, B.G.2
Cohen, R.D.3
-
66
-
-
37549046504
-
-
Remicade® (infliximab) prescribing information. Malvern (PA): Centocor Inc., 2007
-
Remicade® (infliximab) prescribing information. Malvern (PA): Centocor Inc., 2007
-
-
-
-
67
-
-
34247504544
-
Risks and benefits of biologic therapy for inflammatory bowel diseases
-
D' Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007; 56: 725-32
-
(2007)
Gut
, vol.56
, pp. 725-732
-
-
D' Haens, G.1
-
68
-
-
37549010039
-
-
Surveillance, Epidemiology, and End Results Database (SEER) program. SEER incidence crude rates, 11 Registries, 1993-2001. Rockville (MD): National Cancer Institute
-
Surveillance, Epidemiology, and End Results Database (SEER) program. SEER incidence crude rates, 11 Registries, 1993-2001. Rockville (MD): National Cancer Institute
-
-
-
-
69
-
-
37549059671
-
-
Humira® (adalimumab) prescribing information. Chicago (IL): Abbott Laboratories, 2007
-
Humira® (adalimumab) prescribing information. Chicago (IL): Abbott Laboratories, 2007
-
-
-
-
70
-
-
37549031823
-
-
Remicade® (infliximab) for IV injection prescribing information. Malvern (PA): Centocor Inc., 2007
-
Remicade® (infliximab) for IV injection prescribing information. Malvern (PA): Centocor Inc., 2007
-
-
-
-
71
-
-
33646696885
-
Anti TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancy. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
-
Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancy. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 296: 2275-85
-
(2006)
JAMA
, vol.296
, pp. 2275-2285
-
-
Bongartz, T.1
Sutton, A.J.2
Sweeting, M.J.3
-
72
-
-
34347369156
-
Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale?
-
Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007; 13 (8): 1024-30
-
(2007)
Inflamm Bowel Dis
, vol.13
, Issue.8
, pp. 1024-1030
-
-
Rosh, J.R.1
Gross, T.2
Mamula, P.3
-
73
-
-
33846592386
-
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
-
Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-7
-
(2007)
J Pediatr Gastroenterol Nutr
, vol.44
, pp. 265-267
-
-
Mackey, A.C.1
Green, L.2
Liang, L.C.3
|